FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CH
Instruction 1(b).	Filed pursuant to Se

## ANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BRYNJELSEN SEAN						2. Issuer Name and Ticker or Trading Symbol Eton Pharmaceuticals, Inc. [ ETON ]									ationship k all app Direc	,	ng Pei	rson(s) to Is	
(Last) 21925 W	(Fi ' FIELD PH	,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 08/20/2021									X	Officer (give title below)  Presider		nt & (	Other (specif below)	
(Street) DEER PA			0010 Zip)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	·′				
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benefic	cially	/ Own	ed			
Dat				Date	Date Exe Month/Day/Year) if a		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Securi Benefi		ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
							Code	v	Amount	(A) (D)	or Prio	e	Transa	action(s) 3 and 4)			(111301. 4)		
Common	Stock			08/20/	2021				P		10,000	A	\$4	1.32	1,0	030,000 D			
Common	Stock													24,940 I By L				By LLC	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) if any Code (Instr. Derivat of (Month/Day/Year) 8) Securit Acquire				rative rities ired r osed )	Expiration Date (Month/Day/Year) S				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amoun or Number of Shares						

**Explanation of Responses:** 

/s/ W. Wilson Troutman, Attorney-in-fact

08/20/2021

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).